A Phase 2a, Proof of Concept, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women With Moderate to Severe Endometriosis-Related Pain
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Gefapixant (Primary) ; Naproxen
- Indications Endometriosis; Pelvic pain
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2019 Planned End Date changed from 27 Nov 2019 to 16 Jun 2020.
- 10 Jun 2019 Planned primary completion date changed from 27 Nov 2019 to 16 Jun 2020.
- 07 Mar 2019 Planned End Date changed from 22 Oct 2019 to 27 Nov 2019.